

February 22, 2019

VIA ELECTRONIC MAIL

U.S. Nuclear Regulatory Commission
Region III
Division of Nuclear Materials Safety
Attention: Sara Forster, Health Physicist Licensing Reviewer
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

Re: Radioactive Materials Licenses Held by Novartis AG ("Novartis"), Parent of Endocyte, Inc. ("Endocyte"), Holder of Materials License No. 13-32212-01

To Whom It May Concern:

As requested by the U.S. Nuclear Regulatory Commission ("NRC"), please see attached as Exhibit A hereto information regarding radioactive materials licenses granted by the NRC or a U.S. state to which the NRC has granted portions of its regulatory authority (each such state, an "Agreement State"), and held directly by Novartis or by one or more of its subsidiaries (other than Materials License No. 13-32212-01 held by Endocyte).

If you have any questions or need any additional information regarding the subject matter of this letter, please contact:

Leo Bronfman
Global Head of Legal & Compliance
Advanced Accelerator Applications, a Novartis company
4 rue de la Tour de l'île
1204 Geneva
Switzerland
+1-609-955-4419
leo.bronfman@adacap.com

and

G.J. Ligelis Jr.
Cravath, Swaine & Moore LLP
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019

(212) 474-1892
Email: gligelisjr@cravath.com

Respectfully,

Novartis AG



Name: PETER LOUWAGIE

Title: As Attorney

Novartis AG



Name:

Jeffrey Holgate

Title:

As Attorney

EXHIBIT A

NRC and Agreement State Radioactive Materials Licenses

Licensee Name	License Number	Issuing Jurisdiction	Last Inspection Date
Advanced Accelerator Applications	698379	New Jersey – Department of Environmental Protection	05/09/17
Novartis Pharmaceuticals Corporation	507408 – RAD 180001	New Jersey – Department of Environmental Protection	06/07/18
Novartis Institute for Functional Genomics	6655-37	California – Department of Public Health, Radiologic Health Branch	01/15/16
Novartis Institutes for Biomedical Research, Inc.	55-0440	Massachusetts – Department of Public Health, Radiation Control Program	Inspection number 0440-07: 05/27/17 (specific to 105 CMR 120.050 through 120.080); Inspection number 0440-08: 05/27/17 (general license inspection)
Novartis Institutes for Biomedical Research, Inc.	3940-01 – Emeryville	California – Department of Public Health, Radiologic Health Branch	01/29/16 (inspected by the California Health and Welfare Agency, Department of Health Services)

Song, Taehoon

From: Forster, Sara
Sent: Monday, February 25, 2019 8:01 AM
To: Song, Taehoon; Pavon, Sandy; Sandrik, Lauren
Cc: Tomczak, Tammy
Subject: FW: RE: Change of ownership, Materials License No. 13-32212-01, Mail Control Number 610645
Attachments: Endocyte, Inc. - Novartis RAM Licenses Letter (2-22-2019).pdf

Please scan in and return to me. Thank you!

Sara Forster

From: Andrew Norwich [mailto:anorwich@cravath.com]
Sent: Friday, February 22, 2019 3:43 PM
To: Forster, Sara <Sara.Forster@nrc.gov>
Cc: G.J. Ligelis Jr. <GLigelisJr@cravath.com>; Lee Blum <lblum@cravath.com>
Subject: [External_Sender] RE: Change of ownership, Materials License No. 13-32212-01, Mail Control Number 610645

Ms. Forster -

I am following up on my below email. Please see the attached letter regarding certain radioactive materials licenses held by Novartis.

Best,
Andrew

Andrew D. Norwich
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
212.474.1872 | anorwich@cravath.com

From: Andrew Norwich/NYC/Cravath
To: "Forster, Sara" <Sara.Forster@nrc.gov>
Cc: G.J. Ligelis Jr./NYC/Cravath@Cravath, Lee Blum/NYC/Cravath@Cravath
Date: 02/05/2019 05:21 PM
Subject: RE: Change of ownership, Materials License No. 13-32212-01, Mail Control Number 610645

Ms. Forster -

Jessica Barth at Faegre Baker Daniels LLP let us know that you emailed her seeking an update regarding the merger between Endocyte, Inc. and Novartis AG and requesting additional information related to other radioactive materials licenses held by Novartis AG and its subsidiaries.

With respect to the merger, I have re-attached the letter that we sent to you last month confirming the consummation of

the transaction. With respect to the additional information requested by the NRC, we will consult with our client and email you the required information in an attached signed and dated PDF letter.

Please reach out to the Cravath team copied here with any further correspondence regarding Endocyte's pending consent with the NRC. Thank you.

Best,
Andrew

[attachment "Endocyte, Inc. - Notice of Merger Confirmation Letter.pdf" deleted by Andrew Norwich/NYC/Cravath]

Andrew D. Norwich
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
212.474.1872 | anorwich@cravath.com

From: "Forster, Sara" <Sara.Forster@nrc.gov>
To: "Andrew Norwich" <anorwich@cravath.com>
Date: 01/16/2019 11:27 AM
Subject: RE: Change of ownership, Materials License No. 13-32212-01, Mail Control Number 610645

Dear Mr. Norwich,

Thank you for this confirmation of the merger. We will let you know if anything else is needed to complete our review. Also, in accordance with the consummated merger, the referenced radioactive materials license will be amended to reflect commitments made in the consent request.

Sincerely yours,

Sara A. Forster, Health Physicist Licensing Reviewer
U.S. Nuclear Regulatory Commission - Region III
Division of Nuclear Materials Safety
2443 Warrenville Rd. - Ste. 210
Lisle, IL 60532-4352
sara.forster@nrc.gov
Direct: (630) 829-9892
Facsimile: (630) 515-1078



From: Andrew Norwich [<mailto:anorwich@cravath.com>]
Sent: Wednesday, January 16, 2019 10:23 AM
To: Forster, Sara <Sara.Forster@nrc.gov>
Cc: G.J. Ligelis Jr. <GLigelisJr@cravath.com>; Lee Blum <lblum@cravath.com>
Subject: [External_Sender] Change of ownership, Materials License No. 13-32212-01, Mail Control Number 610645

Dear Ms. Forster:

On behalf of Endocyte, Inc., please see the attached requested letter notifying the NRC of the consummation of the merger involving Endocyte. Attached as an exhibit to the letter is an executed copy of the Merger Agreement. Please confirm receipt of the letter.

Please feel free to reach out with any questions or updates to Endocyte's pending request for consent from the NRC.

Regards,
Andrew

Andrew D. Norwich
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
212.474.1872 | anorwich@cravath.com

This e-mail is confidential and may be privileged. Use or disclosure of it by anyone other than a designated addressee is unauthorized. If you are not an intended recipient, please delete this e-mail from the computer on which you received it.

No non - public information is

This e-mail is confidential and may be privileged. Use or disclosure of it by anyone other than a designated addressee is unauthorized. If you are not an intended recipient, please delete this e-mail from the computer on which you received it.

contained herein

-DF 5/10/2019